Actively Recruiting
Clinical Evaluation of Laryngeal Transplantation: Study of 3 Patients
Led by Hospices Civils de Lyon · Updated on 2026-02-17
3
Participants Needed
3
Research Sites
626 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The experience of face and hand composite tissue transplantations reported in the international community have mainly concerned trauma patients. Feasibility and individual benefit have been demonstrated for these indications, in properly selected patients. The first laryngeal transplantation also concerned a case of post-traumatic reconstruction. A certain number of patients, who have suffered direct (extended period of intubation during a stay in the ICU, road traffic accident etc.) or indirect trauma (thermal or chemical burns) to the larynx, present irreversible trauma or injury to the larynx in which conventional treatments are unable to restore laryngeal function. These patients find themselves severely disabled, with a significant reduction in their quality of life. They suffer from stigmatization which leads to social isolation (professional and personal). In some circumstances, providing healthy tissue and anatomical or functional components (cartilage, muscle, nerves, blood vessels) by means of an allogeneic laryngeal transplantation, is the only way of allowing patients, whose quality of life has been seriously affected, to speak, breath and swallow normally. The extremely promising results from other international teams in this area have encouraged the investigators to present this project. The specificities of the protocol compared to previous transplantations carried out by other teams are: * The technique for nerve re-innervation which should make it possible to decannulate all patients and improve functional outcomes in the graft. * A dual therapy immunosuppressive regimen will be used, if the patient's clinical and biological status permits, which can be adjusted according to the type of tissue grafted. It might be thought that the need for immunosuppressive therapy means the indications will remain rare, representing an incidence of less than five patients a year in France. However, the interest of this research project does not reside in the number of patients concerned but rather the total lack of any existing therapeutic solution. Conducting a case series will help determine whether, under certain conditions, laryngeal transplantation can improve the management of patients for whom the usual reconstructive surgery options are unsatisfactory. The study is intended to provide a descriptive analysis of a case series of three laryngeal transplantations before and after comparisons, each patient serving as their own control.
CONDITIONS
Official Title
Clinical Evaluation of Laryngeal Transplantation: Study of 3 Patients
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients with permanent loss of laryngeal function who are tracheotomized, mute, and have failed all three conventional treatments (laser, prosthesis, surgery); diet may be normal
- Adults aged between 18 to 60 years
- ASA score less than 3 and health status compatible with graft and study treatments
- Psychologically balanced, willing, and capable of understanding risks and making informed decisions, as assessed by psychiatrists
- Able to understand study information and consent voluntarily
- Covered by a Health System or compliant with national biomedical research laws
You will not qualify if you...
- Minors or patients over 60 years old
- History of cancer of the upper airways or upper digestive tract, except patients non-smoker with total laryngectomy for laryngeal cancer in remission at least 5 years or low-grade chondrosarcoma fully resected
- Patients already receiving immunosuppressive treatment not matching study protocol
- History of other malignancies
- Progressive malignant tumors or suspicious laryngeal lesions
- Alcohol or smoking addiction within the last 5 years or heavy smoking history
- Hepatitis B, hepatitis C, or HIV infection
- Psychiatric disorders including delusional psychosis, untreated severe depression, severe behavioral disorders, or permanent generalized anxiety
- ASA score 3 or higher
- Moderate renal failure with glomerular filtration rate below 60 mL/min/1.73 m2
- Arterial hypertension treated by more than one therapy
- Positive cross-match test immediately before transplantation
- Pregnant women or women not using effective contraception
- Breastfeeding women
- Legally deprived of freedom or under legal guardianship
- Emergency situation patients
- Epstein-Barr Virus seronegative recipient with seropositive graft due to lymphoma risk
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 3 locations
1
Service d'Urologie et Chirurgie de la Transplantation - Hôpital Edouard Herriot - Hospices Civils de Lyon
Lyon, France, 69003
Actively Recruiting
2
Service ORL & Chirurgie Cervicofaciale - Hôpital Charles Nicolle - CHU Rouen
Rouen, France, 76000
Actively Recruiting
3
Centre de soins de suite et de réadaptation fonctionnelle - SSR Val Rosay
Saint-Didier-au-Mont-d'Or, France, 69370
Actively Recruiting
Research Team
L
Lionel BADET, MD
CONTACT
M
Muriel ROLLAND
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here